Potential Abiomed Class Action
Last Updated on May 1, 2020
Investigation Complete
Attorneys working with ClassAction.org have finished their investigation into this matter. Check back for any potential updates. You can also sign up for our free newsletter for the latest in class action news and settlements.
If you still have questions about your rights, contact an attorney in your area as there is a time limit for filing all lawsuits. The information on this page was posted when the investigation began and is now for reference only.
Free Consumer Tools:
- Open and Current Class Action Lawsuit Settlements and Rebates
- Open and Current Class Action Lawsuit List, Investigations
- Class Action Lawsuit and Settlement News
- Free Class Action Lawsuit Database
At A Glance
- This Alert Affects
- Investors who purchased Abiomed common stock.
- Damages
- These investors may have legal recourse to pursue compensation for damages in light of a recent company disclosure.
- Company(ies)
- Abiomed, Inc.
- Additional Details
- Abiomed is a leading healthcare technology company which has focused itself on developing new technologies to help or replace the pumping function of the heart.
- Date
- On Nov. 1, 2012, Abiomed issued a press release announcing that the U.S. Attorney's Office for the District of Columbia was investigating the company's marketing and labeling of its Impella 2.5 heart pump system.
Attorneys are investigating potential claims that could affect investors who purchased Abiomed common stock. They are looking to determine whether the company violated securities laws following the disclosure of a probe by the Department of Justice and an anticipated FDA review of the marketing and labeling of the company’s Impella 2.5 heart pump system.
On Nov. 1, Abiomed issued a press release announcing that the U.S. Attorney’s Office for the District of Columbia would be investigating marketing and labeling of the Impella 2.5. The company accepted a subpoena related to this investigation and announced that it planned to “cooperate fully.” Abiomed also announced that the FDA will likely convene an advisory panel in Dec. 2012 to review the classification of the Impella heart pump systems and similar products. Following the announcement, the company’s shares fell over 30%.
Before commenting, please review our comment policy.